614 related articles for article (PubMed ID: 9392308)
1. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus.
Sokal EM; Antunes H; Beguin C; Bodeus M; Wallemacq P; de Ville de Goyet J; Reding R; Janssen M; Buts JP; Otte JB
Transplantation; 1997 Nov; 64(10):1438-42. PubMed ID: 9392308
[TBL] [Abstract][Full Text] [Related]
2. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients.
McDiarmid SV; Jordan S; Kim GS; Toyoda M; Goss JA; Vargas JH; MartÃn MG; Bahar R; Maxfield AL; Ament ME; Busuttil RW
Transplantation; 1998 Dec; 66(12):1604-11. PubMed ID: 9884246
[TBL] [Abstract][Full Text] [Related]
3. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression.
Newell KA; Alonso EM; Whitington PF; Bruce DS; Millis JM; Piper JB; Woodle ES; Kelly SM; Koeppen H; Hart J; Rubin CM; Thistlethwaite JR
Transplantation; 1996 Aug; 62(3):370-5. PubMed ID: 8779685
[TBL] [Abstract][Full Text] [Related]
4. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients.
Younes BS; McDiarmid SV; Martin MG; Vargas JH; Goss JA; Busuttil RW; Ament ME
Transplantation; 2000 Jul; 70(1):94-9. PubMed ID: 10919581
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus infections in children after transplantation of the small intestine.
Finn L; Reyes J; Bueno J; Yunis E
Am J Surg Pathol; 1998 Mar; 22(3):299-309. PubMed ID: 9500771
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes in pediatric liver recipients: comparison between cyclosporin A and tacrolimus.
Cao S; Cox KL; Berquist W; Hayashi M; Concepcion W; Hammes GB; Ojogho OK; So SK; Frerker M; Castillo RO; Monge H; Esquivel CO
Pediatr Transplant; 1999 Feb; 3(1):22-6. PubMed ID: 10359027
[TBL] [Abstract][Full Text] [Related]
7. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy.
Cacciarelli TV; Green M; Jaffe R; Mazariegos GV; Jain A; Fung JJ; Reyes J
Transplantation; 1998 Oct; 66(8):1047-52. PubMed ID: 9808490
[TBL] [Abstract][Full Text] [Related]
8. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
Transplantation; 2012 Jan; 93(1):73-81. PubMed ID: 22129761
[TBL] [Abstract][Full Text] [Related]
9. Low-dose immunosuppression reduces the incidence of post-transplant lymphoproliferative disease in pediatric liver graft recipients.
Ganschow R; Schulz T; Meyer T; Broering DC; Burdelski M
J Pediatr Gastroenterol Nutr; 2004 Feb; 38(2):198-203. PubMed ID: 14734884
[TBL] [Abstract][Full Text] [Related]
10. Roles of Epstein-Barr virus viral load monitoring in the prediction of posttransplant lymphoproliferative disorder in pediatric liver transplantation.
Chen HS; Ho MC; Hu RH; Wu JF; Chen HL; Ni YH; Hsu HY; Jeng YM; Chang MH
J Formos Med Assoc; 2019 Sep; 118(9):1362-1368. PubMed ID: 30612881
[TBL] [Abstract][Full Text] [Related]
11. Posttransplant lymphoproliferative disorders and gastrointestinal manifestations of Epstein-Barr virus infection in children following liver transplantation.
Cao S; Cox K; Esquivel CO; Berquist W; Concepcion W; Ojogho O; Monge H; Krams S; Martinez O; So S
Transplantation; 1998 Oct; 66(7):851-6. PubMed ID: 9798693
[TBL] [Abstract][Full Text] [Related]
12. Decreasing incidence of symptomatic Epstein-Barr virus disease and posttransplant lymphoproliferative disorder in pediatric liver transplant recipients: report of the studies of pediatric liver transplantation experience.
Narkewicz MR; Green M; Dunn S; Millis M; McDiarmid S; Mazariegos G; Anand R; Yin W;
Liver Transpl; 2013 Jul; 19(7):730-40. PubMed ID: 23696264
[TBL] [Abstract][Full Text] [Related]
13. Association between liver transplantation for Langerhans cell histiocytosis, rejection, and development of posttransplant lymphoproliferative disease in children.
Newell KA; Alonso EM; Kelly SM; Rubin CM; Thistlethwaite JR; Whitington PF
J Pediatr; 1997 Jul; 131(1 Pt 1):98-104. PubMed ID: 9255199
[TBL] [Abstract][Full Text] [Related]
14. Primary tacrolimus (FK506) therapy and the long-term risk of post-transplant lymphoproliferative disease in pediatric liver transplant recipients.
Cacciarelli TV; Reyes J; Jaffe R; Mazariegos GV; Jain A; Fung JJ; Green M
Pediatr Transplant; 2001 Oct; 5(5):359-64. PubMed ID: 11560756
[TBL] [Abstract][Full Text] [Related]
15. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease.
Smets F; Latinne D; Bazin H; Reding R; Otte JB; Buts JP; Sokal EM
Transplantation; 2002 May; 73(10):1603-10. PubMed ID: 12042647
[TBL] [Abstract][Full Text] [Related]
16. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment.
Guthery SL; Heubi JE; Bucuvalas JC; Gross TG; Ryckman FC; Alonso MH; Balistreri WF; Hornung RW
Transplantation; 2003 Apr; 75(7):987-93. PubMed ID: 12698085
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus--associated posttransplantation lymphoproliferative disorder with tacrolimus metabolism deterioration in infants after living-donor liver transplantation.
Fukushima D; Sato K; Kawagishi N; Ohuchi N; Satomi S
Transplantation; 2015 Jan; 99(1):114-9. PubMed ID: 24846306
[TBL] [Abstract][Full Text] [Related]
18. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression.
Shapiro R; Nalesnik M; McCauley J; Fedorek S; Jordan ML; Scantlebury VP; Jain A; Vivas C; Ellis D; Lombardozzi-Lane S; Randhawa P; Johnston J; Hakala TR; Simmons RL; Fung JJ; Starzl TE
Transplantation; 1999 Dec; 68(12):1851-4. PubMed ID: 10628763
[TBL] [Abstract][Full Text] [Related]
19. Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder.
Davis CL; Harrison KL; McVicar JP; Forg PJ; Bronner MP; Marsh CL
Clin Transplant; 1995 Feb; 9(1):53-9. PubMed ID: 7742583
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression.
Ellis D; Jaffe R; Green M; Janosky JJ; Lombardozzi-Lane S; Shapiro R; Scantlebury V; Vivas C; Jordan ML
Transplantation; 1999 Oct; 68(7):997-1003. PubMed ID: 10532541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]